Registration Dossier

Administrative data

Description of key information

The key study for acute oral toxicity was read across from the structural analogue hexadecanol (CAS 36653-82-4). It reports an LD50 value >2000mg/kg (Hempstoc k, 1996; rel 1). The key study for acute inhalation toxicity is read across from tetradecanol (CAS 112-72-1). A 1 hour LC50 of >1.5mgl was reported, which is the equivalent of 0.375 mg/l for a 4 hour exposure (Scientific Associates, 1977; rel 2). The acute dermal key study is also read across from tetradecanol, with the LD50 value of ca. 8000 mg/kg (Scientific Associates, 1977; rel 2).

Key value for chemical safety assessment

Acute toxicity: via oral route

Endpoint conclusion
Dose descriptor:
2 000 mg/kg bw

Acute toxicity: via inhalation route

Endpoint conclusion
Dose descriptor:
8 000 mg/m³

Additional information

There was no available data for acute toxicity for 1 -pentadecanol. Therefore, key information from structurally related compounds was read across for hazard decisions. For this purpose, data from hexadecanol and tetradecanol was used.

The study for acute inhalation toxicity was selected as read across from 1-tetradecanol as it was the structurally most analogous substance available with the most recent and high reliability information. The reported LC50 value for the study is below the concentration necessary for classification purposes. Furthermore, the saturated vapour concentration (calculated by the reviewer using the ideal gas equation on the basis of the physicocemical properties of 1-tetradecanol) demostrates that the highest theoretically achievable vapour concentration would have been reached or exceeded in this study (4h LC50 value of 0.375 mg/l). Therefore the recorded concentration in the key study represents the highest possible exposure concentration and can be considered for classification purposes.

Justification for classification or non-classification

The data read across from reliable sources of structural analogues suggests that classification and labelling is not required for any of the acute toxicity endpoints, in accordance with CLP (EC regulation 1272/2008).